F. Hoffmann-La Roche Ltd: FDA grants Priority Review to Roche's inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation

Priority Review recognises the best-in-class potential of the inavolisib-based regimen for patients in urgent need of new treatment options1,2Additional analyses of INAVO120 will be presented in an oral

Related Keywords

United States ,Japan ,Switzerland ,San Antonio ,Texas ,America ,American ,Levi Garraway ,Bruno Eschli ,Loren Kalm ,Karsten Kleine ,Sabine Borngr ,Kirti Pandey ,Yvette Petillon ,Birgit Masjost ,Simon Goldsborough ,Sileia Urech ,Nathalie Altermatt ,Rebekka Schnell ,Roche Group ,Head Of Global Product Development ,American Society Of Clinical Oncology Annual Meeting ,Genentech ,Drug Administration ,European Medicines Agency ,Priority Review ,Clinical Oncology Annual ,New Drug Application ,Chief Medical Officer ,Global Product ,Prescription Drug User Fee Act ,European Medicines ,Therapy Designation ,Clinical Oncology Annual Meeting ,Dow Jones Sustainability Indices ,Chugai Pharmaceutical ,Systematic Review ,Diagnostic Workup ,Intj Breast ,San Antonio Breast Cancer Symposium ,Breakthrough Therapy Approvals ,Study Evaluating ,Patients With ,Hormone Receptor Positive ,Locally Advanced ,Metastatic Breast ,Participants With ,Metastatic Breast Cancer Post ,Endocrine Combination ,Combination With Phesgo Versus Placebo ,Combination With Phesgo ,Positive Locally Advanced ,Metastatic Breast Cancer ,Williston Park ,Adv Med ,Ihr Portfolio ,